title: L-NAME-induced protein remodeling and fibrosis in the rat heart.
abstract: The aim of the present study was to determine whether NO deficiency itself or rather the elevation of systolic blood pressure is responsible for the protein and structural remodeling of the heart during hypertension induced by long-term treatment by nitric oxide synthase inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME). Three groups of rats were investigated. The first group served as control. In the second group L-NAME was given in the dose of 20 mg/kg/day in the drinking water and in the third group L-NAME was given in the dose of 40 mg/kg/day during 4 weeks. While L-NAME treatment in both doses caused essentially the same increase in systolic blood pressure (SBP), NO synthase activity and cGMP concentration in the left ventricle decreased by 17% and 13%, respectively in the 20 mg/kg/day L-NAME group and by 69% and 27%, respectively in the 40 mg/kg/day L-NAME group. The protein profile of the left ventricle in both L-NAME groups was characterized by an increased concentration of metabolic proteins. Nevertheless, a significant increase in the concentration of pepsin-soluble collagenous proteins and the concentration of hydroxyproline in pepsin-insoluble collagenous proteins was found only in the group receiving 40 mg/kg/day L-NAME. The morphometric evaluation revealed a significant increase in myocardial fibrosis in both L-NAME groups. However, this was more pronounced in the 40 mg/kg/day L-NAME group. It is concluded that NO deficiency resulted in significant enhancement of fibrotic tissue growth in proportion to the administered L-NAME dose, while SBP was increased similarly in both L-NAME groups. Thus, NO deficiency rather than hemodynamic changes appears to be crucially involved in collagenous protein and fibrotic tissue changes of the left ventricle in hypertension induced by L-NAME.
authors.affiliation: Institute of Normal and Pathological Physiology, Slovak Academy of Sciences, Bratislava, Slovak Republic. pechan@unpf.savba.sk
authors.forename: O
authors.initials: O
authors.lastname: Pechánová
authors.forename: I
authors.initials: I
authors.lastname: Bernátová
authors.forename: V
authors.initials: V
authors.lastname: Pelouch
authors.forename: P
authors.initials: P
authors.lastname: Babál
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D003094:Collagen / Q000096:biosynthesis*; D006152:Cyclic GMP / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004719:Endomyocardial Fibrosis / Q000139:chemically induced / Q000209:etiology*; D004791:Enzyme Inhibitors; D006321:Heart / Q000187:drug effects* / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D006352:Heart Ventricles / Q000378:metabolism / Q000473:pathology; D006909:Hydroxyproline / Q000032:analysis; D006973:Hypertension / Q000139:chemically induced / Q000150:complications; D007150:Immunohistochemistry; D008297:Male; D019331:NG-Nitroarginine Methyl Ester; D009569:Nitric Oxide / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis; D051381:Rats; D017208:Rats, Wistar
chemical_list: D004791:Enzyme Inhibitors; D018809:Proliferating Cell Nuclear Antigen; D009569:Nitric Oxide; D003094:Collagen; D019001:Nitric Oxide Synthase; D006152:Cyclic GMP; D006909:Hydroxyproline; D019331:NG-Nitroarginine Methyl Ester